I am truly amazed how many investors and shareholders just don't get what's going on here (connect the dots). A multi platform drug technology that could be used in:
Disease areas:
a) Parkinsons
b) Diabetes (just received a major. $.5mm grant days ago)
c) Ischemic Heart Disease
d) Retinitis Pigmentosa (Orphan indication already announced)
e) Traumatic Brain injury
f) Cancer
g) Ear (supposedly, this Orphan indication will be announced shortly as well)
A Diagnostic division ...that already has an relationship (alliance_ with Becton Dickinson (for their Alzheimer's based blood test) that should be commercialized by 2014 (over $500mm in potential sales) and has many other Blood based tests for Parkinson's, Breast cancer (in the works) as well.
A strong patent portfolio, and a world class Advisory team with the following backgrounds (Bayer, Novartis, Merck, Bristol Myers Squibb backgrounds along with the Co founder of Amgen ..have been and are still consulting and advising the company on next steps regarding their business plan).
In addition, it entered into a letter of intent to in-license a Phase 2 drug candidate in L-Dopa-Induced Dyskinesia Parkinson’s Disease from an undisclosed third party. Once licensed the Company intends to initiate a Phase 2b clinical trial within 12 months.
Also, it has Dominion Capital who is funding their capital needs and is on board and committed to helping management execute the business plan.
In summary, why would anybody want to sell shares in a company with enormous potential (Market cap only at $34mm....still in its infancy)? GLTA!!!
